Author: Willem van Lawick

Amsterdam-Duivendrecht, The Netherlands, July 26, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders, today announces that at its next General Meeting… Continue reading Kiadis Pharma proposes former Actelion COO Otto Schwarz as new Supervisory Board member

Amsterdam, The Netherlands, June 13, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Euronext Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations for patients suffering from blood cancers and inherited blood disorders safer and more effective, today announces that it has raised €5… Continue reading KIADIS PHARMA RAISES €5 MILLION IN PRIVATE PLACEMENT WITH INSTITUTIONAL INVESTORS

Amsterdam, The Netherlands, April 26, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations for patients suffering from blood cancers and inherited blood disorders safer and more effective, today announces it has submitted a Marketing Authorization… Continue reading Kiadis Pharma announces filing of marketing authorization with the European Medicines Agency for ATIR101™ in blood cancers

~ Regulatory approval received from the national authority in Belgium to start pivotal Phase III trial with ATIR101™ and from the national authority in Germany to start the Phase I/II trial with ATIR201™ ~ Amsterdam, The Netherlands, April 3, 2017, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a… Continue reading Kiadis Pharma announces positive regulatory update on ATIR101™ and ATIR201™

~ Paves the way for submission of a Marketing Authorization Application for ATIR101™ in Europe ~ Amsterdam, The Netherlands, March 28, 2017, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces… Continue reading Kiadis Pharma’s Pediatric Investigation Plan for ATIR101™ accepted by the European Medicines Agency’s Pediatric Committee